Lunasin and ALS

ALS, also known as Lou Gehrig's disease, is a debilitating condition that causes the nerves cells in the brain and spinal cord to degenerate, leading to loss of muscle and motor functioning. Until recently, there was little hope for ALS patients to see any improvement in symptoms, let alone signs of disease reversal, following months or years of the disease's advancement.

However, lunasin shows promise in slowing ALS progression by reducing neural inflammation and oxidative stress, two factors that are excessively present in ALS patients. Lunasin's anti-inflammatory and antioxidant effects can reduce free radical production by activated macrophages and scavenge free radicals. Targeting these abnormalities is the focus of ALS clinical trials. Furthermore, studies have shown that lunasin can inhibit the release of pro-inflammatory cytokines like IL-6 and TNF-α, as well as NO, PGE2, and COX-2.